Test of Cure After Epclusa Treatment
Yes, a test of cure (sustained virologic response) is required after completing Epclusa therapy—specifically, HCV RNA testing should be performed at 12 weeks post-treatment (SVR12), with routine confirmation recommended at 48 weeks post-treatment. 1
Testing Timeline
Initial Confirmation (SVR12)
- Test at 12 weeks after completing treatment with undetectable HCV RNA (<15 IU/mL) to confirm sustained virologic response 1
- This SVR12 timepoint has replaced the older SVR24 standard and is now the primary endpoint for determining cure 1
- SVR12 is tantamount to virologic cure, with fewer than 1% of patients experiencing late relapse after achieving this milestone 1
Routine Follow-up (SVR48)
- Routine confirmation at 48 weeks post-treatment is recommended for all patients 1
- Testing at 24 weeks post-treatment should be considered on an individual patient basis 1
- Routine testing beyond 48 weeks is NOT supported by available evidence unless the patient has ongoing risk factors for reinfection 1
Risk-Based Ongoing Monitoring
After confirming SVR at 12 and 48 weeks, periodic HCV RNA testing is only recommended for patients with ongoing risk factors for reinfection, including:
- Active injection drug use
- Men who have sex with men with high-risk sexual practices
- Other ongoing exposure risks 1
Post-SVR Surveillance Based on Fibrosis Stage
The most recent EASL 2024 guidance emphasizes that ongoing clinical follow-up depends on baseline fibrosis stage, not on repeated viral testing 2:
Patients WITHOUT Advanced Fibrosis (F0-F2)
- No HCC surveillance needed 1
- Can be discharged from specialized hepatology care after confirming SVR
Patients WITH Advanced Fibrosis or Cirrhosis (F3-F4)
- HCC surveillance with liver imaging ± AFP every 6 months indefinitely 1
- Endoscopic screening for varices in all cirrhotic patients, independent of SVR 1
- Repeat endoscopy at 2-3 years if no varices or small varices found initially 1
Clinical Rationale
The evidence strongly supports that SVR12 represents virologic cure with extremely low relapse rates (<1%) in clinical trials 1, 3. The 48-week confirmation provides additional reassurance but is primarily for documentation purposes rather than expectation of finding late relapse. The shift from intensive viral monitoring to risk-stratified surveillance reflects the excellent efficacy of modern direct-acting antivirals like Epclusa, where treatment success rates exceed 95-99% across all genotypes 3, 4.
Common pitfall to avoid: Do not continue indefinite HCV RNA testing in patients who achieve SVR12 and SVR48 without reinfection risk factors—this represents unnecessary testing and healthcare costs without clinical benefit 1.